ArticleAnnals of translational medicine2022

Anlotinib plus nab-paclitaxel/gemcitabine as first-line treatment prolongs survival in patients with unresectable or metastatic pancreatic adenocarcinoma: a retrospective cohort.

Hongyang Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.